Hepatic encephalopathy following transjugular intrahepatic portosystemic shunt (TIPS): Management with L-ornithine-L-aspartate and stent reduction

Metabolic Brain Disease

Volumn 22, Issue 1, 2007, Pages 45-50

  Stadlbauer, Vanessa ^a,b   Tauss, Josef ^a   Portugaller, Horst R ^a   Stiegler, Philipp ^a   Iberer, Florian ^a   Stauber, Rudolf E ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Hepatic encephalopathy; L ornithine L aspartate; Stent reduction; Transjugular intrahepatic portosystemic shunt; Venous ammonia levels

Indexed keywords

FUROSEMIDE; LACTULOSE; ORNITHINE ASPARTATE; SPIRONOLACTONE;

AGED; ARTICLE; ASCITES; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE SEVERITY; ESOPHAGUS; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; PORTOSYSTEMIC ANASTOMOSIS; TREATMENT OUTCOME;

AGED; AMMONIA; DIPEPTIDES; HEPATIC ENCEPHALOPATHY; HUMANS; LIVER DISEASES, ALCOHOLIC; LIVER TRANSPLANTATION; MALE; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; POSTOPERATIVE COMPLICATIONS; STENTS;

EID: 33847653732     PISSN: 08857490     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11011-006-9032-3     Document Type: Article

References (30)

1. Als-Nielsen B, Gluud LL, Gluud C (2004) Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 328:1046-1052
2. Blei AT, Olafsson S, Therrien G, Butterworth RF (1994) Ammonia-induced brain edema and intracranial hypertension in rats after portacaval anastomosis. Hepatology 19:1437-1444
3. Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Seeff L, Levy LL (1977) Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 72:573-583
4. Cordoba J, Dupuis J, Gottstein J, Blei AT (1997) Stenosis of a portacaval anastomosis affects circadian locomotor activity in the rat: A multivariable analysis. Am J Physiol 273:G1218-G1225
5. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT (2002) Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 35:716-721
6. Fleig WE, Kircheis G, Spengler U, Zeuzem ST, Gortelmeyer R, The German-Austrian-Swiss Multicenter Study Group (1999) Placebo-controlled, double-blind evaluation of L-ornithine-L-aspartate (LOLA) granules in patients with cirrhosis and subclinical (SHE) or mild overt hepatic encephalopathy (HE). J Hepatol 30:65 (abstract)
7. Gines P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, Planas R, Bosch J, Arroyo V, Rodes J (2002) Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 123:1839-4187
8. Hauenstein KH, Haag K, Ochs A, Langer M, Rossle M (1995) The reducing stent: treatment for transjugular intrahepatic portosystemic shunt-induced refractory hepatic encephalopathy and liver failure. Radiology 194:175-179
9. Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Gortelmeyer R, Hendricks R, Kruger B, Kuklinski B, Meister H, Otto HJ, Rink C, Rosch W, Stauch S (1997) Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 25:1351-1360
10. Klempnauer J, Schrem H (2001) Review: surgical shunts and encephalopathy. Metab Brain Dis 16:21-25
11. Lebrec D, Giuily N, Hadengue A, Vilgrain V, Moreau R, Poynard T, Gadano A, Lassen C, Benhamou JP, Erlinger S (1996) Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: A randomized trial French Group of Clinicians and a Group of Biologists. J Hepatol 25:135-144
12. Leonhardt H, Bungert HJ (1972) Therapie der schweren Hyperammoniaemie. Med Klin 67:1052-1056
13. Lozeva V, Montgomery JA, Tuomisto L, Rocheleau B, Pannunzio M, Huet PM, Butterworth RF (2004) Increased brain serotonin turnover correlates with the degree of shunting and hyperammonemia in rats following variable portal vein stenosis. J Hepatol 40:742-748
14. Luca A, D'Amico G, La Galla R, Midiri M, Morabito A, Pagliaro L (1999) TIPS for prevention of recurrent bleeding in patients with cirrhosis: meta-analysis of randomized clinical trials. Radiology 212:411-421
15. Madoff DC, Wallace MJ, Ahrar K, Saxon RR (2004) TIPS-related hepatic encephalopathy: Management options with novel endovascular techniques. Radiographics 24:21-36
16. Ochs A, Rossle M, Haag K, Hauenstein KH, Deibert P, Siegerstetter V, Huonker M, Langer M, Blum HE (1995) The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med 332:1192-1197
17. Olde Damink SW, Jalan R, Redhead DN, Hayes PC, Deutz NE, Soeters PB (2002) Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology 36:1163-1171
18. Quiroga J, Sangro B, Nunez M, Bilbao I, Longo J, Garcia-Villarreal L, Zozaya JM, Betes M, Herrero JI, Prieto J (1995) Transjugular intrahepatic portal systemic shunt in the treatment of refractory ascites: Effect on clinical, renal, humoral, and hemodynamic parameters. Hepatology 21:986-994
19. Riggio O, Merli M, Pedretti G, Servi R, Meddi P, Lionetti R, Rossi P, Bezzi M, Salvatori F, Ugolotti U, Fiaccadori F, Capocaccia L (1996) Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt Incidence and risk factors. Dig Dis Sci 41:578-584
20. Rose C, Michalak A, Pannunzio P, Therrien G, Quack G, Kircheis G, Butterworth RF (1998) L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: Therapeutic efficacy and mechanism of action. Metab Brain Dis 13:147-57
21. Rose C, Michalak A, Rao, KV, Quack G, Kircheis G, Butterworth RF (1999) L-ornithine-L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure. Hepatology 30:636-640
22. Rose C, Butterworth RF, Zayed J, Normandin L, Todd K, Michalak A, Spahr L, Huet PM, Pomier-Layrargues G (1999) Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction. Gastroenterology 117:640-644
23. Rossle M, Ochs A, Gulberg V, Siegerstetter V, Holl J, Deibert P, Olschewski M, Reiser M, Gerbes AL (2000) A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 342:1701-1707
24. Saab S, Nieto J, Ly, D, Runyon B (2004) TIPS versus paracentesis for cirrhotic patients with refractory ascites. Cochrane Database Syst Rev 3:CD004889
25. Salerno F, Merli M, Riggio O, Cazzaniga M, Valeriano V, Pozzi M, Nicolini A, Salvatori F (2004) Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 40:629-635
26. Sanyal AJ, Genning C, Reddy KR, Wong F, Kowdley KV, Benner K, McCashland T (2003) North American study for the treatment of refractory ascites group the North American study for the treatment of refractory ascites. Gastroenterology 124:634-641
27. Somberg KA, Riegler JL, LaBerge JM, Doherty-Simor MM, Bachetti P, Roberts JP, Lake JR (1995) Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: Incidence and risk factors. Am J Gastroenterol 90:549-555
28. Stauch S, Kircheis G, Adler G, Beckh K, Ditschuneit H, Gortelmeyer R, Hendricks R, Heuser A, Karoff C, Malfertheiner P, Mayer D, Rosch W, Steffens J (1998) Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: Results of a placebo-controlled double-blind study. J Hepatol 28:856-864
29. Ter Borg PC, Hollemans M, Van Buuren HR, Vleggaar FP, Groeneweg M, Hop WC, Lameris JS (2004) Transjugular intrahepatic portosystemic shunts: long-term patency and clinical results in a patient cohort observed for 3-9 years. Radiology 231:537-545
30. Wong F, Sniderman K, Liu P, Allidina Y, Sherman M, Blendis L (1995) Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann Intern Med 122:816-822